Table 3.
SARS-CoV and MERS-CoV HR2 based inhibitory peptides data. The inhibition data describes IC or analogous values reported for the various inhibitors in blocking infection of SARS-CoV or MERS-CoV infection. As the procedures to test inhibition varied among different groups, the different viral strains and cell lines are noted. The * for P21S10 refers to the position of the residue used to form the staple.
| Virus | Peptide Name | Sequence | Inhibition Data | References |
|---|---|---|---|---|
| SARS-CoV | HR2-8 | ELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIK | EC50: 17 μM (SARS-CoV Strain 5688 infection of Vero E6 cells) | Bosch et al. (2004) |
| SARS-CoV | CP-1 | GINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYE | IC50: 19 μM (SARS-CoV Strain WHU infection of Vero E6 cells) | Liu et al. (2004) |
| SARS-CoV | HR1-1 | NGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTSTA | EC50: 0.14 μM (HIV pseudotyped SARS-CoV S infection of VeroE6 cells) EC50: 3.68 μM (SARS-CoV Strain BJ01 infection of Vero E6 cells) |
Yuan et al. (2004) |
| SARS-CoV | HR2-18 | IQKEIDRLNEVAKNLNESLIDLQELGK | EC50: 1.19 μM (HIV pseudotyped SARS-CoV S infection of VeroE6 cells) EC50: 5.22 μM (SARS-CoV Strain BJ01 infection of Vero E6 cells) |
Yuan et al. (2004) |
| SARS-CoV | P6 | YQDVNCTDVSTAIHADQLTP | IC90: 113 μM (SARS-CoV Strain GZ50 infection of FRhK-4 cells) | Zheng et al. (2005) |
| SARS-CoV | P8 | QYGSFCTQLNRALSGIAAEQ | IC90: 24.9 μM (SARS-CoV Strain GZ50 infection of FRhK-4 cells) | Zheng et al. (2005) |
| SARS-CoV | P10 | IQKEIDRLNEVAKNLNESLI | IC90: 73.5 μM (SARS-CoV Strain GZ50 infection of FRhK-4 cells) | Zheng et al. (2005) |
| SARS-CoV | P6+P8+P10 | IC90: 0.9 μM (SARS-CoV Strain GZ50 infection of FRhK-4 cells | Zheng et al. (2005) | |
| SARS-CoV | SR9 | ISGINASVVNIQKEIRLNEVAKNLNESLIDLQEL | EC50: <100 nM (SARS-CoV infection of Vero E6 cells with trypsin treatment) | Ujike et al. (2008) |
| SARS-CoV | HR2P | DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | IC50: 2.81 μM (HIV pseudotyped SARS-CoV S infection of ACE2/293T cells) | Xia et al. (2019) |
| MERS-CoV | P1 | LTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL | IC50: 3 μM (HIV pseudotyped MERS-CoV S infection of Huh7 cells) | Gao et al. (2013) |
| MERS-CoV | HR2P | SLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKEL | IC50: 0.6 μM (MERS-CoV EMC/2012 infection of Huh7 cells) IC50: 0.6 μM (MERS-CoV EMC/2012 infection of Calu-3 cells) IC50: 13.9 μM (MERS-CoV EMC/2012 infection of HFL cells) |
Lu et al. (2014) |
| MERS-CoV | HR2P-M2 | SLTQINTTLLDLEYEMKKLEEVVKKLEESYIDLKEL | IC50: 0.55 μM (MERS-CoV S mediated HEK293T and Huh7 cell-cell fusion) | Lu et al. (2014) |
| MERS-CoV | P21S10 | LDLTYEMLSLQQVV K*LNE*Y | EC50: 3.03 μM (HIV pseudotyped MERS-CoV S infection of Huh7 cells) | Wang et al. (2018) |
| SARS-CoV-2 | 2019-nCoV-HR2P | DISGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL | IC50: 0.98 μM (Pseudotyped SARS-CoV-2 S infection of ACE2/293T cells) | Xia et al. (2020) |
| Pan-CoV | EK1 | SLDQINVTFLDLEYEMKLEEAIKLEESYIDLKEL | IC50: 0.26 μM (HIV pseudotyped MERS-CoV S infection of Huh7) IC50: 0.62 μM (MERS-CoV Strain EMC/2012 infection of Calu-3 cells) IC50: 2.23 μM (HIV pseudotyped SARS-CoV S infection of ACE2/293T cells) IC50: 2.38 μM (Pseudotyped SARS-CoV-2 S infection of ACE2/293T cells) |
(Xia et al., 2020, 2019) |